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Abstract: The Top Journal Selectivity Index (TJSI) is a scientometric index reflecting the 
potential importance of a new drug. It represents the ratio of the number of all types of articles 
on a particular drug in the top 20 journals relative to the number of articles in all (.5,000) 
biomedical journals covered by Medline over the 5 years since the drug’s introduction. The 
TJSI can be an indicator of a drug’s potential for sustained use: a higher score increases the 
probability of continuing success.
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Introduction
Scientometric methods can be used to show potentially fruitful areas for drug discovery, 
based on the assumption that higher levels of scientific activity, including publication 
rates, will point to specific targets for novel therapies.1 Bordons et al demonstrated 
the usefulness of bibliometric analyses to detect trends in the research of a therapeutic 
drug including the evolution of drug studies over time.2 Can a scientometric indicator 
reflecting initial drug “coverage” in biomedical journals be used to assess a specific 
drug’s potential?
The first attempt to predict the clinical success of drugs by using bibliometric data 
was made by Windsor in 1976.3 Later he wrote, “Just as rabbits leave rabbit tracks and 
  squirrels leave squirrel tracks – successful drugs leave different bibliometric tracks 
than do unsuccessful drugs. Sometimes these track records can be used to make predic-
tions.”4 He used bibliometric traits of the journal literature on levodopa over a 14-year 
period to identify predictors of the drug’s success. He concluded that the bibliometry 
of single-author papers may have promise in this regard.
In 2011 a scientometric indicator, the Top Journal Selectivity Index (TJSI), was 
suggested for use in the assessment of therapeutic drugs.5 It represents the ratio 
(as percentage) of the number of all types of articles on a particular drug in the top 
20 journals relative to the number of articles in all (.5000) biomedical journals covered 
by Medline over the 5 years since the drug’s introduction. Five years is a relatively 
long period of time, but the accurate assessment of a drug’s value takes much longer. 
The true assessment of a drug usually comes with the confirmation of its effective-
ness by meta-analyses (the process of combining results of many clinical studies to 
draw conclusions about the therapeutic value of a drug). The conclusion on a drug’s 
value reached via this process can take 10–20 years.6 However, even this period 
may not be sufficient, because the comparison of various drugs in meta-analyses is 
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usually indirect, using a placebo as a common comparator.7 
As a result such comparisons are not often reliable; only 
direct head-to-head comparisons between drugs can provide 
dependable information on drugs’ relative efficacy. Thus an 
accurate conclusion on a drug’s value via this process can 
take longer than 20 years. The relatively rapid (3–5 years) 
publication response to a new drug may have an important 
predictive power related to the whole period of a drug’s 
protracted evaluation.
In the assessment of the success of new analgesics over 
the past 50 years, we observed a difference in the publica-
tion response to a new drug between biomedical journals 
in general and in the top journals: the number of published 
articles on a drug increased (or declined) more rapidly in the 
top journals.6 This observation prompted the introduction of 
TJSI as an early indicator of drug success. This feature of 
TJSI can probably be explained by the high-caliber experts 
involved in the assessment of manuscripts evaluating new 
drugs in the top specialty journals.
TJSI determinants
One of the TJSI determinants is the number of all types of 
journal articles with or without abstracts (including editorials, 
case reports, reviews, and letters to the editor) covered by the 
Web site of US National Library of Medicine – PubMed (see 
http://www.ncbi.nlm.nih.gov/PubMed). PubMed comprises 
over 21 million citations for the biomedical literature and 
covers approximately 5000 journals. The PubMed Web site 
was used to count the number of articles in English published 
in all types of journals (original research and review journals). 
Specific keywords were selected according to the name of a 
selected drug. Boolean operations were used in which vari-
ables were the selected keywords and years of publications.
Another TJSI determinant is the number of articles 
published in the 20 top journals (also counted using the 
PubMed Web site). The selection of the Top 20 Journals 
was based on two factors: the rank of a journal sorted by 
(1) the Impact Factor and (2) the journal specialty area 
related to the drug’s specific pharmacological class. Sixteen 
journals were common for all selected drugs. They represent 
medicine in general (10 journals) and pharmacology (six 
journals): Ann Intern Med, Annu Rev Pharmacol Toxicol, 
BMJ, Clin Pharmacol Ther, J Clin Invest, J Pharmacol 
Exp Ther, JAMA, Lancet, N Engl J Med, Nat Med, Nat Rev 
Drug Discov, Nature, Pharmacol Rev, Proc Natl Acad Sci 
U S A, Science, and Trends Pharmacol Sci. Four additional 
items were selected depending on each drug specialty area. 
For example, in the case of drugs used by neurologists the 
selected journals were: Ann Neurology, Brain, Nat Neurosci, 
and Trends Neurosci. Journals were sorted by the rank of 
their Impact Factor presented by Journal Citation Reports, 
Science Edition (see http://science.thomsonreuters.com). 
The choice of the specific journals is more important than 
the total number of top journals. When we used 100 top 
journals instead of 20, the difference in the values of TJSI 
was not distinct. It should be noted that the chosen determi-
nants are not mutually exclusive; one relies on a subject of 
the information used to create the other. Figure 1 gives an 
example of TJSI calculated in this manner for drugs in six 
pharmacological classes when the first-in-class drug (FICD) 
had multiple follow-on drugs (FOD). The duration of 5 years 
assessment period since drug introduction can be changed. 
The assessment period could be decreased to 3 years if the 
increase in the rate of publications in all journals is suffi-
ciently high from the very beginning.
Relationship between TJSI and 
success score for analgesic drugs
Ten analgesics approved by the US Federal Drug Adminis-
tration (FDA) during the period 1986–2009 were selected 
for analysis.5 They included new molecular entities (NME) 
developed as analgesics and also drugs developed for nonpain 
indications with subsequent FDA approval for the treatment 
of pain as an additional indication: sumatriptan, tramadol, 
remifentanil, gabapentin, zolmitriptan, celecoxib, ziconotide, 
pregabalin, topiramate, and duloxetine. In counting the 
numbers of articles published over the 5 years since a drug’s 
introduction, specific keywords were selected according 
to the name of an analgesic in addition to using PubMed 
Medical Subject Heading [MeSH] terms. Terms added to 
the name of a drug were “pain” OR “headache disorder” 
[MeSH] OR “migraine”.
The analgesic success score was determined based on the 
following criteria: (1) novelty of molecular target (completely 
novel target, novel modification of existing target, or incre-
mental improvement of existing drug); (2) analgesic efficacy 
(magnitude of pain relief, strength of evidence regarding 
effectiveness, and universality in use); and (3) response by the 
pharmaceutical market (based on the number of NME similar 
to the initial drug). The contributions of these three criteria to 
the total success score were weighted differently: much more 
weight was given to analgesic efficacy (up to the maximum 
of 5 points) than to the two other criteria (up to the maximum 
of 2 points each). The strength of the relationship between 
TJSI and success score was quite impressive: r = 0.876, 
P , 0.001 (Figure 2). Even if the “outlier”   sumatriptan is 
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not taken into account, the correlation coefficient continues 
to be high at 0.694 (P , 0.05).
TJSI was compared with two other bibliometric indices: 
the number of all types of articles presented in PubMed 
(AJI) and the number of articles covering only randomized 
controlled trials (RCT). It was found that although there was 
some tendency for positive relationships between the “all 
articles” index (or “RCT articles”) and the success score, 
these relationships did not reach statistical significance.
The TJSI approach is purely statistical. There are other 
approaches trying to find relationships between the suc-
cess rate of drugs and different factors of drugs research 
performance. The most interesting in this report is the study 
by Koenig.9 He defined the Composite Drug Output Index, 
which served as a good predictor for past (or) future success. 
His finding of a high correlation between the number of all 
published articles and expert judgment of the quality of 
pharmaceutical research is of particular interest. His data 
also indicated that the number of highly cited clinical articles 
correlated with drug research success (assessed by expert 
judgment) even better than the number of all clinical articles. 
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Figure 1 Example of Top Journal Selectivity Indices (TJSI) of first-in-class drugs (FICD) with multiple follow-on drugs (FOD) in six pharmacological classes. 
Note: Columns represent TJSI: the ratio of the number of all types of articles on a particular drug in the top 20 journals to the number of articles in all (.5000) biomedical 
journals covered by Medline (PubMed), both over 5 years since the drug’s introduction.
Abbreviations: ACE, angiotensin-converting enzyme; PPI, proton pump inhibitors; NRTI, nucleotide reverse transcriptase inhibitors.
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Figure 2 The relationship between TJSI and success score in the development of 
new analgesics.
Note:  The  correlation  coefficient  (r)  for  TJSI  and  success  score  is  0.876 
(P , 0.001).
Abbreviations: TJSI, Top Journals Selectivity Index; To, topiramate; D, duloxetine; 
P,  pregabalin;  Zo,  zolmitriptan;  Tr,  tramadol;  R,  remifentanil;  Zi,  ziconotide; 
C, celecoxib; G, gabapentin; S, sumatriptan.
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Because the top biomedical journals selected for our index 
calculations have a much higher citation rate than the rest 
of the journals, the previously mentioned better correlation 
rate for highly cited clinical articles compared to all clinical 
articles could service as an indication going in the same 
direction as our conclusion.
TJSI detects difference between 
breakthrough and follow-on drugs  
in various pharmacological classes
Two groups of drugs were selected to test the hypothesis that 
the difference between the most successful (breakthrough) 
and less successful drugs of the same category can be 
detected by TJSI.8 The FDA Web site for approved drug 
products (see http://www.fda.gov/Drugs) was used for selec-
tion of drugs approved between 1980–1989. One group of 
10 agents included the most successful (breakthrough) drugs 
belonging to different pharmacological classes. The other 
group of 10 drugs was selected using a paired design: the 
paired drug belonged to the same pharmacological group 
with a mechanism of action as similar as possible. The selec-
tion of drugs for both groups was based on two principles: 
the degree of advancement in the new drug development 
and the level of commercial success. The drug in the first 
group had a novel mechanism of action and also a highly 
competitive market status (six or more pharmaceutical 
companies had applied to the FDA for a generic alternative). 
The drug in the second group provided only an incremental 
improvement on the existing drug and had a lower market-
ing status as a generic drug (one to five pharmaceutical 
companies applied to the FDA). The following breakthrough 
drugs were included: acyclovir, buprenorphine, captopril, 
diltiazem, enalapril, fluoxetine, gemfibrozil, lovastatin, 
omeprazole, and zidovudine. The paired group of drugs 
included: abacavir, alfentanil, felodipine, fenofibrate, flu-
vastatin, foscarnet, lansoprazole, maprotiline, moexipril, 
and perindopril.
The two groups were compared using three publication 
indices: the TJSI, the number of all types of articles on a drug 
in journals covered by PubMed (AJI), and the number of 
articles presenting only randomized controlled trials (RCT). 
It was found that TJSI can detect the difference between the 
two groups of drugs better than the two other indices. The 
results indicated that the mean TJSI of the breakthrough 
drugs was much higher than that of similar, but less success-
ful, drugs (18.6 ± 2.9 vs 7.4 ± 4.2, difference of 11.2 ± 5.2; 
P , 0.0001). For the AJI the mean difference between the 
groups was 423 ± 457 (P , 0.02), and for the RCT index 
the mean difference was statistically insignificant (8 ± 42; 
P . 0.5).
Table 1 indicates that the higher value of TJSI was always 
that of the breakthrough member of a pair. With AJI, the 
value of a breakthrough member was higher, in only eight 
of 10 pairs. With RCT, the value of an index was higher 
with a breakthrough member in only four of 10 pairs. The 
percentage of times that an index for the breakthrough drug 
was higher than that of its corresponding pair, and related 
95% confidence interval (CI) is presented in Table 1. The 
table indicates that the TJSI was distinguishable from random 
chance was 100% of the time with a 95% CI at 69% and 100%. 
For the AJI, the value was 80% of the time with a 95% CI 
at 44% and 98%. For the RCT index, the distinguishability 
from random chance was 40% of the time with a 95% CI 
at 12% and 74%. Thus, TJSI will detect the breakthrough 
drug at least 69% of the time with 95% confidence. For the 
other two indices, their CIs contain 50%, and thus they are 
not distinguishable from random chance (50%) in selecting 
the breakthrough drug. Thus, TJSI can detect the difference 
between a breakthrough drug and a less successful drug from 
the same pharmacological class.
TJSI and “me-too” drugs
Usually the introduction of a FICD is followed by the devel-
opment of many similar drugs, referred to as FOD. While 
some FOD have pharmacological properties that distinguish 
them from the FICD, others do not. Drugs without distin-
guishing features are often called “me-too” drugs, because 
they offer no significant benefits (including safety) over the 
previous agents.10 The marketing of each new drug without 
Table 1 Comparison of paired drugs
n Paired couples TJSI AJI RCT
1 Acyclovir vs doscarnet + + +
2 Buprenorphine vs alfentanil +
3 Captopril vs moexipril + + +
4 Diltiazem vs felodipine + +
5 Enalapril vs perindopril + + +
6 Fluoxetine vs maprotiline + + +
7 Gemfibrozil vs fenofibrate +
8 Lovastatin vs fluvastatin + +
9 Omeprazole vs lansoprazole + +
10 Zidovudine vs abacavir + +
Distinguishability from random  
chance
100% 80% 40%
95% CI 69%–100% 44%–98% 12%–74%
Note: Plus indicates when the index for the breakthrough drug was higher than that 
of the compared drug in a couple.
Abbreviations: CI, confidence interval; TJSI, Top Journals Selectivity Index; AJI, All 
Journals Index; RCT, randomized controlled trials.
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distinguishing features becomes questionable, especially 
when the sequential number of the market entry is as high 
as five or more.
It was shown that TJSI can provide help in the assessment 
of late market entrants without distinguishing features.11 
To prove that there is a relationship between the TJSI of 
  “me-too” drugs and the order (sequential number) of their 
market entry, the 43 FOD without distinguishing features 
were assessed. The study was based on drug classes approved 
by the FDA for marketing between the 1960s and early 2000s. 
The eight pharmacological classes that had four or more 
drugs were included for analysis. Five specific indicators 
were used to identify FOD with distinguishing pharmacologi-
cal properties. The analysis of the remaining 43 FOD without 
such distinguishing properties demonstrated (Figure 3) that 
the relationship between TJSIs for FODs and the order of the 
drugs’ market entry had a negative correlation (r = −0.372; 
P = 0.014): the higher the order (sequential number), the 
lower the TJSI.
The negative correlation between FOD without distin-
guishing features and the order of market entry can be used 
for the identification of “me-too” drugs. It was found that 
if TJSI is less than 0.5 of FICD and market entry order is 
5 or higher, the FOD is a “me-too” drug (with false negative 
rate of only 9.1%.) The FICD and the first three FODs that 
followed it were excluded from this analysis to eliminate the 
possibility of counting as “me-too” drugs those that might 
be involved in the process of competition for being the first 
drug in a new class.
To underline the notion that the determinants of the TJSI 
are not mutually exclusive one can indicate that with each new 
‘me-too’ drug a reasonable increase in the number of publica-
tions on the related NME could occur. This would increase 
both the TJSI and the AJI for the NME. Among quantitative 
studies regarding the effect of FODs order-of-entry on the 
drugs’ commercial success there was a publication indicat-
ing that despite the average success of pioneers over later 
entrants, there are examples of opposite phenomenon; later 
entrants have gained dominant market share.12
The development and the marketing of “me-too” drugs has 
been criticized as duplicative, wasting resources that should 
be used instead to develop more innovative products.13,14 The 
view that investment in the development of “me-too” drugs 
is not an effective use of community resources dates back to 
the 1959 Kefauer US Senate committee review.15 Since that 
time many arguments have been made on both sides of the 
debate regarding how many “me-too” drugs is too many.16 
Identifying which FOD offer no significant benefits over 
previous agents, ie, how to distinguish “me-too” drugs among 
FOD is a difficult question, and the TJSI could confirm the 
presence of a ‘me-too’ drug among FODs.
Conclusion
TJSI is a scientometric index reflecting the potential impor-
tance of a new drug and can be an indicator for sustained 
use of a drug: a higher score increases the probability of 
continuing success.
The universality of the TJSI has important limitations. 
Studies on drugs with narrow, limited use do not have many 
publications; some of such studies are not published. In addi-
tion, many drugs do not have studies published in top-ranked 
journals. For example, among the 14 analgesics analyzed 
previously5 only 10 had enough publications to calculate 
the TJSI. Four drugs (ketorolac, pentosan, topical lidocaine, 
and valproate) were excluded from the calculations, either 
because they did not have sufficient number of publications 
in the All Journal category (more than 10 articles) or not a 
single article in the Top 20 Journals category.
The other TJSI limitation is that this index does not differ-
entiate between publications characterizing a drug in a posi-
tive and negative way. Sometimes after a drug introduction 
(due to the possible discovery of unexpected adverse effects) 
a significant number of articles can be devoted to the serious 
problems associated with its administration. For example, in 
2001–2008, publications on the cardiovascular risk related to 
cycloxygenase-2 (COX-2) selective inhibitors reached up to 
12% of all publications on COX-2 inhibitors.6
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The evaluation of the TJSI is based on the three presented 
examples. The real-life utility of this index for various 
groups of drugs and different situations should be further 
explored.
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